Comparison of diffusion-weighted imaging and enhanced T1-weighted sequencing in patients with multiple sclerosis
- PMID: 28452571
- PMCID: PMC5524272
- DOI: 10.1177/1971400916678224
Comparison of diffusion-weighted imaging and enhanced T1-weighted sequencing in patients with multiple sclerosis
Abstract
Introduction The purpose of this study was to assess whether demographic, brain anatomical regions and contrast enhancement show differences in multiple sclerosis (MS) patients with increased diffusion lesions (ID group) compared with diffusion restriction (DR group). Method MRI protocol comprised T1- and T2-weighted sequences with and without gadolinium (Gd), and sagittal three-dimensional FLAIR sequence, DWI and ADC maps were prospectively performed in 126 MS patients from January to December 2015. The investigation was conducted to evaluate differences in demographic, cord and brain regional, technical, and positive or negative Gd contrast imaging parameters in two groups of ID and DR. Statistical analysis was performed by using SPSS. Results A total of 9.6% of patients showed DR. In the DR group, 66.6% of the patients showed contrast enhancement of plaques, whereas 29.2% of the IR group showed enhancement of plaques. The most prevalent group was non-enhanced plaques in the ID group, followed by Gd-enhanced plaques in the ID group. Patients in the ID group (90.4%) were significantly more than in the DR group (9.6%). Out of the 40 patients with Gd-enhanced plaques, 80.5% was from the ID group and 19.5% from the DR group. Conclusion MRI of the brain, unlike of the cord, with Gd demonstrates significant difference in enhancement between the two groups ( p < 0.05). No significant difference was seen in demographic, cord and brain regional, and technical parameters, EDSS, disease duration, and attack rate as well as demographic and regional parameters between the ID and decrease diffusion groups ( p > 0.05).
Keywords: Multiple sclerosis; diffusion restriction; diffusion-weighted imaging; increased diffusion.
Similar articles
-
Correlation between contrast enhanced plaques and plaque diffusion restriction and their signal intensities in FLAIR images in patients who admitted with acute symptoms of multiple sclerosis.J Med Imaging Radiat Sci. 2021 Mar;52(1):121-126. doi: 10.1016/j.jmir.2020.12.001. Epub 2021 Jan 11. J Med Imaging Radiat Sci. 2021. PMID: 33446443
-
The evaluation of MRI diffusion values of active demyelinating lesions in multiple sclerosis.Mult Scler Relat Disord. 2016 Nov;10:97-102. doi: 10.1016/j.msard.2016.09.006. Epub 2016 Sep 28. Mult Scler Relat Disord. 2016. PMID: 27919508
-
The contribution of diffusion-weighted MR imaging in multiple sclerosis during acute attack.Eur J Radiol. 2008 Mar;65(3):421-6. doi: 10.1016/j.ejrad.2007.05.002. Epub 2007 Jun 22. Eur J Radiol. 2008. PMID: 17587524
-
New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions.J Neuroradiol. 2020 Jun;47(4):250-258. doi: 10.1016/j.neurad.2020.01.083. Epub 2020 Jan 31. J Neuroradiol. 2020. PMID: 32014494 Review.
-
Using diffusion-weighted MRI in multicenter clinical trials for multiple sclerosis.J Neurol Sci. 2001 May 1;186 Suppl 1:S51-4. doi: 10.1016/s0022-510x(01)00492-0. J Neurol Sci. 2001. PMID: 11334990 Review.
Cited by
-
Potential Biomarkers Associated with Multiple Sclerosis Pathology.Int J Mol Sci. 2021 Sep 25;22(19):10323. doi: 10.3390/ijms221910323. Int J Mol Sci. 2021. PMID: 34638664 Free PMC article. Review.
-
Current and Future Biomarkers in Multiple Sclerosis.Int J Mol Sci. 2022 May 24;23(11):5877. doi: 10.3390/ijms23115877. Int J Mol Sci. 2022. PMID: 35682558 Free PMC article. Review.
-
Multiple sclerosis: prevalence of the 'central vein' sign in white matter lesions on gadolinium-enhanced susceptibility-weighted images.Neuroradiol J. 2021 Oct;34(5):470-475. doi: 10.1177/19714009211008750. Epub 2021 Apr 19. Neuroradiol J. 2021. PMID: 33872085 Free PMC article.
-
Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023 Mar;167(1):30-35. doi: 10.5507/bp.2023.002. Epub 2023 Jan 25. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023. PMID: 36695545
References
-
- McFarland HF, Martin R. Multiple sclerosis: A complicated picture of autoimmunity. Nat Immunol 2007; 8: 913–919. - PubMed
-
- Rodriguez M, Siva A, Ward J, et al. Impairment, disability, and handicap in multiple sclerosis: A population-based study in Olmsted County, Minnesota. Neurology 1994; 44: 28–33. - PubMed
-
- Hauser SL, Goodin DS. Multiple sclerosis and other demyelinating diseases. In: Braunwald E, Fauci AS, Kasper DL, et al. (eds). Harrison’s principles of internal medicine, New York: McGraw-Hill, 2001, pp. 2452–2461.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical